Axsome Therapeutics (19X) Stock Forecast & Price Target

5 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

19X Analyst Ratings

Strong Buy

15 Buy

1 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Axsome

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

19X Stock 12 Month Forecast

Average Price Target

€256.89

▲(43.43% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is €256.89 with a high forecast of €339.10 and a low forecast of €220.42. The average price target represents a 43.43% change from the last price of €179.10.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"100":"€100","160":"€160","220":"€220","280":"€280","340":"€340"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":339.1043544,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€339.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":256.886421456,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€256.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":220.41783036,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€220.42</span>\n  </div></div>","useHTML":true}}],"tickPositions":[100,160,220,280,340],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,162.35,175.9464888,189.5429776,203.1394664,216.73595519999998,230.332444,243.92893279999998,257.52542159999996,271.1219104,284.7183992,298.314888,311.91137679999997,325.50786559999995,{"y":339.1043544,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,162.35,169.6220324196923,176.8940648393846,184.1660972590769,191.43812967876923,198.71016209846152,205.98219451815385,213.25422693784614,220.52625935753846,227.79829177723076,235.07032419692308,242.34235661661538,249.61438903630767,{"y":256.886421456,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,162.35,166.81675618153847,171.2835123630769,175.75026854461538,180.21702472615385,184.68378090769232,189.15053708923077,193.61729327076924,198.08404945230768,202.55080563384615,207.01756181538462,211.4843179969231,215.95107417846154,{"y":220.41783036,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":101.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.7,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.9,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.45,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":196.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":213.3,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":192.15,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.3,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":162.35,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€339.10

Average Price Target€256.89

Lowest Price Target€220.42

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Leonid Timashev

RBC Capital

€263.25

Buy

46.99%

Upside

Reiterated

10/14/26

Analysts Offer Insights on Healthcare Companies: Starling Oncology Institute (NASDAQ: STLN), Axsome Therapeutics (NASDAQ: AXSM) and Contineum Therapeutics, Inc. Class A (NASDAQ: CTNM)

Evan Seigerman

BMO Capital

€276.64

Buy

54.46%

Upside

Reiterated

10/12/26

Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Axsome Therapeutics (AXSM)

Jason Gerberry

Bank of America Securities

€246.3

Buy

37.52%

Upside

Reiterated

10/09/26

Axsome Therapeutics (AXSM) Gets a Buy from Bank of America Securities

Matthew Hershenhorn

Oppenheimer

€249.87

Buy

39.51%

Upside

Reiterated

10/06/26

Analysts' Top Healthcare Picks: Axsome Therapeutics (AXSM), AbbVie (ABBV)

Benjamin Burnett

Wells Fargo

€228.45

Buy

27.55%

Upside

Assigned

10/01/26

Wells Fargo Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

David Hoang

Deutsche Bank

€249.87→€238.27

Buy

33.03%

Upside

Reiterated

09/29/26

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO), ClearPoint Neuro (NASDAQ: CLPT) and Axsome Therapeutics (NASDAQ: AXSM)

Sean Laaman

Morgan Stanley

€220.42

Hold

23.07%

Upside

Reiterated

09/25/26

Axsome Therapeutics price target lowered to $247 from $251 at Morgan StanleyAxsome Therapeutics price target lowered to $247 from $251 at Morgan Stanley

Ram Selvaraju

H.C. Wainwright

€258.79

Buy

44.49%

Upside

Reiterated

09/25/26

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), Scholar Rock Holding (NASDAQ: SRRK) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Srikripa Devarakonda

Truist Financial

€178.48→€254.33

Buy

42.00%

Upside

Initiated

09/23/26

Axsome Therapeutics (AXSM) Has a New Rating from Truist Financial

David Amsellem

Piper Sandler

€230.23

Buy

28.55%

Upside

Reiterated

09/18/26

Piper Sandler Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

Graig Suvannavejh

Mizuho Securities

€281.99

Buy

57.45%

Upside

Reiterated

09/11/26

Axsome rises as Mizuho highlights 'big month-over-month jump' for AuvelityAxsome rises as Mizuho highlights 'big month-over-month jump' for Auvelity

Andrew Tsai

Jefferies

€339.1

Buy

89.34%

Upside

Reiterated

08/11/26

Analysts Offer Insights on Healthcare Companies: Cardinal Health (NYSE: CAH), Axsome Therapeutics (NASDAQ: AXSM) and BridgeBio Pharma (NASDAQ: BBIO)

Ami Fadia

Needham

€238.27→€239.16

Buy

33.53%

Upside

Reiterated

08/10/26

Ami Fadia Reiterates Buy on Axsome as Auvelity Outperformance and Alzheimer’s Agitation Launch Momentum Offset Near-Term Margin Pressure

Myles Minter

William Blair

―

Buy

―

Reiterated

08/10/26

Myles Minter Reiterates Buy on Axsome as Auvelity Outperformance and AXS-12 NDA Acceptance Strengthen Long-Term Growth Outlook

Yatin Suneja

Guggenheim

€232.02→€245.4

Buy

37.02%

Upside

Reiterated

08/10/26

Axsome Therapeutics price target raised to $275 from $260 at GuggenheimAxsome Therapeutics price target raised to $275 from $260 at Guggenheim

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Leonid Timashev

RBC Capital

€263.25

Buy

46.99%

Upside

Reiterated

10/14/26

Analysts Offer Insights on Healthcare Companies: Starling Oncology Institute (NASDAQ: STLN), Axsome Therapeutics (NASDAQ: AXSM) and Contineum Therapeutics, Inc. Class A (NASDAQ: CTNM)

Evan Seigerman

BMO Capital

€276.64

Buy

54.46%

Upside

Reiterated

10/12/26

Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Axsome Therapeutics (AXSM)

Jason Gerberry

Bank of America Securities

€246.3

Buy

37.52%

Upside

Reiterated

10/09/26

Axsome Therapeutics (AXSM) Gets a Buy from Bank of America Securities

Matthew Hershenhorn

Oppenheimer

€249.87

Buy

39.51%

Upside

Reiterated

10/06/26

Analysts' Top Healthcare Picks: Axsome Therapeutics (AXSM), AbbVie (ABBV)

Benjamin Burnett

Wells Fargo

€228.45

Buy

27.55%

Upside

Assigned

10/01/26

Wells Fargo Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

David Hoang

Deutsche Bank

€249.87→€238.27

Buy

33.03%

Upside

Reiterated

09/29/26

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO), ClearPoint Neuro (NASDAQ: CLPT) and Axsome Therapeutics (NASDAQ: AXSM)

Sean Laaman

Morgan Stanley

€220.42

Hold

23.07%

Upside

Reiterated

09/25/26

Axsome Therapeutics price target lowered to $247 from $251 at Morgan StanleyAxsome Therapeutics price target lowered to $247 from $251 at Morgan Stanley

Ram Selvaraju

H.C. Wainwright

€258.79

Buy

44.49%

Upside

Reiterated

09/25/26

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), Scholar Rock Holding (NASDAQ: SRRK) and Vertex Pharmaceuticals (NASDAQ: VRTX)

Srikripa Devarakonda

Truist Financial

€178.48→€254.33

Buy

42.00%

Upside

Initiated

09/23/26

Axsome Therapeutics (AXSM) Has a New Rating from Truist Financial

David Amsellem

Piper Sandler

€230.23

Buy

28.55%

Upside

Reiterated

09/18/26

Piper Sandler Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)

Graig Suvannavejh

Mizuho Securities

€281.99

Buy

57.45%

Upside

Reiterated

09/11/26

Axsome rises as Mizuho highlights 'big month-over-month jump' for AuvelityAxsome rises as Mizuho highlights 'big month-over-month jump' for Auvelity

Andrew Tsai

Jefferies

€339.1

Buy

89.34%

Upside

Reiterated

08/11/26

Analysts Offer Insights on Healthcare Companies: Cardinal Health (NYSE: CAH), Axsome Therapeutics (NASDAQ: AXSM) and BridgeBio Pharma (NASDAQ: BBIO)

Ami Fadia

Needham

€238.27→€239.16

Buy

33.53%

Upside

Reiterated

08/10/26

Ami Fadia Reiterates Buy on Axsome as Auvelity Outperformance and Alzheimer’s Agitation Launch Momentum Offset Near-Term Margin Pressure

Myles Minter

William Blair

―

Buy

―

Reiterated

08/10/26

Myles Minter Reiterates Buy on Axsome as Auvelity Outperformance and AXS-12 NDA Acceptance Strengthen Long-Term Growth Outlook

Yatin Suneja

Guggenheim

€232.02→€245.4

Buy

37.02%

Upside

Reiterated

08/10/26

Axsome Therapeutics price target raised to $275 from $260 at GuggenheimAxsome Therapeutics price target raised to $275 from $260 at Guggenheim

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

EHCEncompass Health

MDWDMediwound

OVIDOvid Therapeutics

ARDXArdelyx

STOKStoke Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Axsome Therapeutics

3 Months

Joseph ThomeTD Cowen

Success Rate

18/28 ratings generated profit

Average Return

+17.90%

Copying Joseph Thome's trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +17.90% per trade.

1 Year

Joseph ThomeTD Cowen

Success Rate

21/28 ratings generated profit

Average Return

+51.21%

Copying Joseph Thome's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +51.21% per trade.

2 Years

Graig SuvannavejhMizuho Securities

Success Rate

36/44 ratings generated profit

Average Return

+57.28%

Copying Graig Suvannavejh's trades and holding each position for 2 Years would result in 81.82% of your transactions generating a profit, with an average return of +57.28% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

19X Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 19X has received 31 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 19X average Analyst price target in the past 3 months is 256.89.

Each month's total comprises the sum of three months' worth of ratings.

19X Financial Forecast

19X Earnings Forecast

Next quarter’s earnings estimate for 19X is -€0.51 with a range of -€0.89 to -€0.03. The previous quarter’s EPS was -€0.88. 19X beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 19X has Performed in-line its overall industry.

19X Sales Forecast

Next quarter’s sales forecast for 19X is €225.49M with a range of €203.33M to €251.55M. The previous quarter’s sales results were €194.86M. 19X beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 19X has Performed in-line its overall industry.

19X Stock Forecast FAQ

What is DE:19X’s average 12-month price target, according to analysts?

Based on analyst ratings, Axsome Therapeutics Inc’s 12-month average price target is 256.89.

What is DE:19X’s upside potential, based on the analysts’ average price target?

Axsome Therapeutics Inc has 43.43% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Axsome Therapeutics Inc a Buy, Sell or Hold?

Axsome Therapeutics Inc has a consensus rating of Strong Buy, which is based on 15 buy ratings, 1 hold ratings and 0 sell ratings.

What is Axsome Therapeutics Inc’s share price target?

The average share price target for Axsome Therapeutics Inc is 256.89. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €339.10 ,and the lowest forecast is €220.42. The average share price target represents 43.43% Increase from the current price of €179.1.

What do analysts say about Axsome Therapeutics Inc?

Axsome Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of Axsome Therapeutics Inc?

To buy shares of DE:19X, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Axsome Therapeutics (19X) Stock Forecast & Price Target

19X Analyst Ratings

19X Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Axsome Therapeutics

19X Analyst Recommendation Trends

19X Financial Forecast

19X Earnings Forecast

19X Sales Forecast

19X Stock Forecast FAQ

Detailed List of Analyst Forecasts